

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAAXH1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	27	AUG 13	CA/CAPplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	28	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	29	AUG 15	CAPplus currency for Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 01:21:58 ON 18 AUG 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 01:22:08 ON 18 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 AUG 2008 HIGHEST RN 1041334-94-4

DICTIONARY FILE UPDATES: 15 AUG 2008 HIGHEST RN 1041334-94-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\ahughes\My Documents\10529552.str

L1          STRUCTURE UPLOADED

=> s l1 sss sam

SAMPLE SEARCH INITIATED 01:22:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -          1 TO ITERATE

100.0% PROCESSED          1 ITERATIONS          0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*  
                             BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:          1 TO          80

PROJECTED ANSWERS:              0 TO          0

L2 0 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 01:22:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1


=> d scan

L3 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-, (R\*,R\*)- (9CI)

MF C25 H37 N3 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-


MF C25 H37 N3 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 3 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN  
IN 4-Imidazolidineheptanoic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-  
MF C31 H41 N3 O5

PAGE 1-A



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

178.36

TOTAL

SESSION

178.57

FILE 'CAPLUS' ENTERED AT 01:23:00 ON 18 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Aug 2008 VOL 149 ISS 8  
FILE LAST UPDATED: 17 Aug 2008 (20080817/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3

L4 27 L3

=> s food or diet

431325 FOOD

225067 DIET

L5 623299 FOOD OR DIET

=> s l5 and l4

L6 0 L5 AND L4

=> d ibib hitstr abs l4 1-27

L4 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:710468 CAPLUS

DOCUMENT NUMBER: 145:306558

TITLE: Platelet-activating factor antagonists protect amyloid- $\beta$  damaged neurons from microglia-mediated death

AUTHOR(S): Bate, Clive; Kempster, Sarah; Williams, Alun

CORPORATE SOURCE: Department of Pathology and Infectious Diseases, Royal Veterinary College, North Mymms, Hertfordshire, Hatfield, AL9 7TA, UK

SOURCE: Neuropharmacology (2006), 51(2), 173-181

CODEN: NEPHBW; ISSN: 0028-3908

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 118675-50-6, BWA868C

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(platelet-activating factor antagonists protect amyloid- $\beta$  damaged neurons from microglia-mediated death)

RN 118675-50-6 CAPLUS

CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)



AB Neurons treated with sub-lethal concns. of amyloid- $\beta$ 1-42 developed phenotypic changes and selectively bound a CD14-IgG chimera; in co-cultures, microglia recognized and killed these amyloid- $\beta$ 1-42-damaged neurons. Pre-treatment with the platelet-activating factor (PAF) antagonists (Hexa-PAF, CV6209 or ginkgolide B) reduced CD14-IgG binding to amyloid- $\beta$ 1-42-damaged neurons, and the presence of PAF antagonists in co-cultures increased neuronal survival in a dose-dependant manner. PAF antagonists also protected neurons treated with HuPrP82-146, a peptide found in prion diseases. Second messenger studies demonstrated that the addition of PAF mimicked some of the effects of amyloid- $\beta$ 1-42 on neurons. PAF-damaged neurons bound CD14-IgG, and PAF-damaged neurons were killed by microglia in a CD14-dependent process. Neuronal death was inversely related to both the concentration of PAF, and the number of microglia added. The effects of PAF were reduced by an antagonist of the prostanoïd D receptor (BWA868C) indicating that neuronal damage induced by PAF is partly mediated by prostaglandins. These observations are compatible with the hypothesis that sub-lethal concns. of amyloid- $\beta$ 1-42 stimulate a cascade of second messengers including PAF and the prostaglandins. At nanomolar concns. PAF induces a change in neuronal phenotype that activates microglia via the CD14 mol., these activated microglia then kill the amyloid- $\beta$ 1-42 damaged neurons.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1223926 CAPLUS

DOCUMENT NUMBER: 144:209973

TITLE: Predisposition to colorectal cancer in rats with resolved colitis. Role of cyclooxygenase-2-derived prostaglandin D2

AUTHOR(S): Zamuner, Stella R.; Bak, Adrian W.; Devchand, Pallavi R.; Wallace, John L.

CORPORATE SOURCE: Mucosal Inflammation Research Group, University of Calgary, Calgary, AB, Can.

SOURCE: American Journal of Pathology (2005), 167(5), 1293-1300

CODEN: AJPAAA; ISSN: 0002-9440

PUBLISHER: American Society for Investigative Pathology

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 118675-50-6, BWA868c

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(increased colonic aberrant crypt formation was reduced by rofecoxib or BWA868c in postcolitis rat)

RN 118675-50-6 CAPLUS

CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)



AB Colitis markedly increases the risk of developing colon cancer, but the underlying mechanisms are not fully understood. In a rat model of colitis, alterations in epithelial secretion, proliferation, and barrier function persist long after healing has occurred. In the present study, we examined whether rats that have recovered from a bout of colitis are more susceptible to preneoplastic lesions and whether this susceptibility is mediated by cyclooxygenase (COX)-2-derived prostaglandin (PG) D<sub>2</sub>. Colitis was induced by intracolonic administration of trinitrobenzenesulfonic acid. Six weeks later, weekly treatment with the carcinogen azoxymethane was initiated. Postcolitis rats exhibited significantly more aberrant crypt foci after azoxymethane treatment than controls. The postcolitis rats also exhibited markedly increased colonic PGD<sub>2</sub> synthesis and elevated COX-2, H-PGD synthase, and  $\beta$ -catenin expression. Treatment for 1 wk with a selective COX-2 inhibitor or with a selective PGD<sub>2</sub> receptor (DP1) antagonist significantly reduced susceptibility of postcolitis rats to aberrant crypt foci development,  $\beta$ -catenin expression, and mucosal thickness. The results from this animal model suggest that prolonged elevation of COX-2-derived PGD<sub>2</sub> synthesis after resolution of colitis may contribute significantly to colitis-associated increases in colon cancer incidence. PGD<sub>2</sub> may therefore represent a rational target for therapies directed at reducing the incidence of colitis-associated colorectal cancer.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:450697 CAPLUS

DOCUMENT NUMBER: 142:476280

TITLE: Reduction of hair growth with prostaglandin DP receptor agonist

INVENTOR(S): Hwang, Cheng Shine; Ahluwalia, Gurpreet S.; Shander, Douglas

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050112075	A1	20050526	US 2003-721118	20031125

CA 2539986	A1	20050609	CA 2004-2539986	20041124
WO 2005051335	A1	20050609	WO 2004-US39693	20041124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2004014915	A	20061107	BR 2004-14915	20041124
EP 1729718	A1	20061213	EP 2004-812253	20041124
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
MX 2006PA04407	A	20060614	MX 2006-PA4407	20060420
PRIORITY APPLN. INFO.:			US 2003-721118	A 20031125
			WO 2004-US39693	W 20041124
IT 118675-50-6				
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (reduction of hair growth with prostaglandin DP receptor agonist)				
RN 118675-50-6 CAPLUS				
CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)				



AB Mammalian hair growth is reduced by applying an agonist of prostaglandin DP-receptor. PGD2 and its analogs demonstrated a significant reduction of human hair follicle growth. Cream formulations and hydroalcoholic formulations are presented.


L4 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2005:405062 CAPLUS  
DOCUMENT NUMBER: 142:423877  
TITLE: Remedies for muscle degenerative disease containing hematopoietic prostaglandin D synthase inhibitors, and method for drug screening for muscle degenerative disease  
INVENTOR(S): Urade, Yoshihiro; Eguchi, Naomi; Aritake, Kosuke; Sato, Akira; Taniike, Masako; Mori, Ikuko; Miyano, Masashi  
PATENT ASSIGNEE(S): Osaka Bio Science Research Institute, Japan; The Institute of Physical & Chemical Research Riken



SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005119984	A	20050512	JP 2003-353917	20031014
US 20050272767	A1	20051208	US 2004-919473	20040817
US 7238718	B2	20070703		

PRIORITY APPLN. INFO.: JP 2003-353917 A 20031014  
 IT 118675-50-6, BW A 868C  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (remedies for muscle degenerative disease containing hematopoietic prostaglandin D synthase inhibitors, and method for drug screening for muscle degenerative disease)  
 RN 118675-50-6 CAPLUS  
 CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)



AB The invention relates to a remedy for muscle degenerative disease, e.g. muscular dystrophy, characterized by containing a hematopoietic prostaglandin D synthase (H-PGDS) inhibitor as an active component. A method for drug screening for muscle degenerative disease by using bupivacaine hydrochloride-induced muscle degeneration of human H-PGDS-expressing transgenic mice is also disclosed. The effect of oral administration of HQL-79 in bupivacaine hydrochloride-induced muscle degenerative disease model mice was examined. A gelatin hard capsule containing HQL-79 10, starch 50, magnesium stearate 10 mg was formulated.

L4 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:310974 CAPLUS  
 DOCUMENT NUMBER: 140:315080  
 TITLE: Novel uses of prostaglandin D2, prostaglandin D2 agonist and prostaglandin D2 antagonist  
 INVENTOR(S): Yoshikawa, Masaaki; Takagi, Kuniko; Ohinata, Kousaku; Inui, Akio; Asakawa, Akihiro; Kakudo, Shinji  
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent

LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030674	A1	20040415	WO 2003-JP7837	20030620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003242485	A1	20040423	AU 2003-242485	20030620
EP 1547598	A1	20050629	EP 2003-733521	20030620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050215609	A1	20050929	US 2005-529552	20050510
PRIORITY APPLN. INFO.:			JP 2002-285637	A 20020930
			WO 2003-JP7837	W 20030620

OTHER SOURCE(S): MARPAT 140:315080

IT 118675-50-6 118675-50-6D, salts


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(novel uses of prostaglandin D2, prostaglandin D2 agonist and prostaglandin D2 antagonist)


RN 118675-50-6 CAPLUS

CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)



RN 118675-50-6 CAPLUS

CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)



AB It is intended to provide novel uses of PGD2, a PGD2 agonist and a PGD2 antagonist. More specifically, use of PGD2 and a PGD2 agonist as eating promoters and use of a PGD2 antagonist as an eating inhibitor.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:246500 CAPLUS

DOCUMENT NUMBER: 140:386368

TITLE: Effects of prostaglandin D2 on helper T cell functions

AUTHOR(S): Tanaka, Kazuya; Hirai, Hiroyuki; Takano, Shoichi; Nakamura, Masataka; Nagata, Kinya

CORPORATE SOURCE: Department of Advanced Medicine and Development, BML, Inc., Saitama, 350-1101, Japan

SOURCE: Biochemical and Biophysical Research Communications (2004), 316(4), 1009-1014

CODEN: BBRC9; ISSN: 0006-291X

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 118675-50-6, BWA868C


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(prostaglandin D2 effects on cytokine production and expression of functional cell-surface mols. in human helper T cells using selective agonists and an antagonist for DP and CRTH2 receptors)

RN 118675-50-6 CAPLUS

CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)


relative efficacies for a series of novel bicyclic ligands. With an appendix on goodness-of-fit analyses  
 Leff, P.; Giles, H.  
 AUTHOR(S): Anal. Pharmacol. Group, Wellcome Res. Lab.,  
 CORPORATE SOURCE: Beckenham/Kent, BR3 3BS, UK  
 SOURCE: British Journal of Pharmacology (1992), 106(4),  
 996-1003  
 CODEN: BJPCBM; ISSN: 0007-1188  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 118675-50-6, BWA868C  
 RL: BIOL (Biological study)  
 (prostaglandin D2 receptor determination with, in jugular vein and human  
 platelets)  
 RN 118675-50-6 CAPLUS  
 CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-  
 dioxo-1-(phenylmethyl)- (CA INDEX NAME)




AB The DP receptors located on platelets and vasculature were examined in a human washed platelet preparation and in isolated rings of rabbit external jugular vein. A series of eight novel bicyclic compds. were studied for their effects in the two assays. Seven produced agonism, inhibition of aggregation or vascular relaxation, and one compound was 'silent' in both assays. The operational model of agonism was fitted simultaneously to concentration-effect curve data for the seven agonist compds. The affinity and efficacy ests. so obtained were tested for similarity between the two tissues by anal. of variance, showing that the model could be fitted to both sets of data by assuming the same relative affinity and efficacy values. However, absolute affinity ests. were consistently lower in the vascular preparation. Anal. of two of the seven agonists as antagonists was also possible. This provided pKB ests. which supported the agonist affinity ests. The eighth compound was also analyzed as an antagonist. It, like the other seven, demonstrated a difference in affinity between the two tissues. The results of this study supported the view that platelet and vascular DP receptors are similar, assuming that the systemic difference in affinity ests. for the series of compds. between the two tissues is the consequence of receptor micro-environment and/or accessory binding site differences.

L4 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1989:129194 CAPLUS  
 DOCUMENT NUMBER: 110:129194  
 ORIGINAL REFERENCE NO.: 110:21183a,21186a  
 TITLE: Antagonism of PGD2 vasodepressor responses in the rat  
 in vivo by the novel, selective antagonist, BW A868C

AUTHOR(S): Hamid-Bloomfield, S.; Whittle, B. J. R.  
 CORPORATE SOURCE: Dep. Pharmacol., Wellcome Res. Lab., Beckenham/Kent,  
 BR3 3BS, UK  
 SOURCE: British Journal of Pharmacology (1989), 96(2), 307-12  
 CODEN: BJPCBM; ISSN: 0007-1188  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 118675-50-6, BW-A 868C  
 RL: BIOL (Biological study)  
 (as PGD2 receptor selective antagonist)  
 RN 118675-50-6 CAPLUS  
 CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-  
 dioxo-1-(phenylmethyl)- (CA INDEX NAME)




GI



AB Bolus i.v. injection of prostaglandin D2 (PGD2) (1-160 µg/kg), the hydantoin prostanoid BW 245C (0.25-160 µg/kg), or prostacyclin (PGI2) (0.05-0.5 µg/kg) caused a dose-dependent fall in systemic arterial blood pressure (BP) in the anesthetized rat, lasting 2-4 min. I.v. infusion of the novel 3-benzyl substituted hydantoin BW A868C (I) (1-10 µg/kg/min), in doses that had no direct effect on BP, dose-dependently reduced the vasodepressor action of PGD2. Bolus injection of BW A868C (30 and 100 µg/kg, i.v.) likewise dose-dependently antagonized the vasodepressor responses to PGD2, causing a 3.4- and 13.2-fold rightward shift of the dose-response curve. The thromboxane-receptor antagonist BM 13.177 (2.5 mg/kg, i.v.) had little effect on the PGD2 vasodepressor responses, suggesting minimal contribution of a PGD2 interaction at thromboxane receptor-sites in the systemic vasculature of this species. BW A86C (10 µg/kg/min, i.v.) caused a rightward shift (59-fold) of the dose-response relationship for BW 245C, the putative PGD2-receptor agonist. This antagonism lasted for at least 1 h after termination of the BW A8678C infusion. Higher doses of BW A868C (20-100 µg/kg/min) caused no further antagonism of the vasodepressor responses to BW 245C,

suggesting that this prostanoid also act at vascular receptors other than of the DP-type. BW A868C (10 µg/kg/min, i.v.) failed to alter after the vasodepressor actions of prostacyclin. These in vivo results support the characterization of BW A868C as a potent and selective antagonist of the cardiovascular actions of PGD2 at the DP-receptor.


L4 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1989:129193 CAPLUS  
 DOCUMENT NUMBER: 110:129193  
 ORIGINAL REFERENCE NO.: 110:21183a,21186a  
 TITLE: The antagonism by BA A868C of PGD2 and BW245C activation of human platelet adenylate cyclase  
 AUTHOR(S): Trist, D. G.; Collins, B. A.; Wood, J.; Kelly, M. G.; Robertson, A. D.  
 CORPORATE SOURCE: Dep. Biochem., Wellcome Res. Lab., Beckenham/Kent, BR3 3BS, UK  
 SOURCE: British Journal of Pharmacology (1989), 96(2), 301-6  
 CODEN: BJPCBM; ISSN: 0007-1188  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 118675-50-6, BW-A 868C  
 RL: BIOL (Biological study)  
 (adenylate cyclase of human blood platelet activation by BW245C and PGD2 antagonism by)  
 RN 118675-50-6 CAPLUS  
 CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)




AB In glycerol-lysed human platelets, PGD2 and the hydantoin BW245C both activate adenylate cyclase in a biphasic manner. These activations are qual. different from those of carbacyclin, iloprost, and PGE2 whose E/[A] curves can be adequately described by rectangular hyperbolae. PGE1 had E/[A] curves of slope significantly lower than that expected for a rectangular hyperbola. The selective PGD2 antagonist BW A868C shifts the 1st phase of the PGD2 and BW245C E/[A] curves but has no effect on the 2nd phase. Applying a 2nd-receptor model enables a pKB to be derived for BW A868C of 9.11. BW A868C has no effect on carbacyclin, iloprost, prostacyclin, PGE1, and PGE2 at a concentration 1000-fold that of its KB against PGD2 and BW245C. Thus PGD2 and BW245C are capable of activating adenylate cyclase in human platelets through the DP-receptor and by another mechanism as yet uncharacterized.

L4 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1989:129192 CAPLUS

DOCUMENT NUMBER: 110:129192  
ORIGINAL REFERENCE NO.: 110:21183a,21186a  
TITLE: The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist  
AUTHOR(S): Giles, Heather; Leff, P.; Bolofo, Mary L.; Kelly, M. G.; Robertson, A. D.  
CORPORATE SOURCE: Dep. Pharmacol., Wellcome Res. Lab., Beckenham/Kent, BR3 3BS, UK  
SOURCE: British Journal of Pharmacology (1989), 96(2), 291-300  
CODEN: BJPCBM; ISSN: 0007-1188  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 118675-50-6, BW-A 868C  
RL: BIOL (Biological study)  
(as prostaglandin DP receptor antagonist, in human and laboratory animal)  
RN 118675-50-6 CAPLUS  
CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)



GI



I

AB BW A868C (I), a novel compound, behaved as a simple competitive antagonist in a human washed platelet aggregation assay. Anti-aggregatory concentration-effect curves to BW 245C were displaced in a parallel manner.

The

shifts accorded with a Schild plot slope of unity and a  $pK_B$  of 9.26. Inhibition of platelet aggregation by PGD<sub>2</sub> was antagonized with a similar potency, as were the relaxation effects of BW 245C and PGD<sub>2</sub> in the rabbit jugular vein. BW A868C can, therefore, be classified as a DP-receptor antagonist. Actions of BW A868C at other prostaglandin receptors (IP, EP<sub>1</sub>, EP<sub>2</sub>, TP, and FP) were excluded at concns. 1000-fold higher than the

DP-receptor affinity. Analyses of BW 245C- and PGD2-mediated effects were complicated by addnl. agonist receptor interactions which were revealed by BW A868C. In rabbit jugular vein a resistant phase of agonism was detectable, indicating that both agonists exerted effects through another receptor (possibly EP2). Also, PGD2, in addition to its anti-aggregatory effect on platelets, demonstrated a pro-aggregatory action in the presence of BW A868C. The contractile effects of PGD2 in guinea pig tracheal strips were resistant to 10  $\mu$ M BW A868C, indicating that they were not mediated through DP-receptors. This is the 1st account of a well-classified competitive antagonist at the DP-receptor. Its potency and selectivity make it an important new tool in prostanoid receptor classification and identification.

L4 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:75504 CAPLUS

DOCUMENT NUMBER: 110:75504

ORIGINAL REFERENCE NO.: 110:12481a,12484a

TITLE: Preparation of substituted hydantoin as PGD2 receptor antagonists, useful for treatment of mast cell dysfunction

INVENTOR(S): Robertson, Alan Duncan; Kelly, Michael Gerard; Wallace, Paul Neil; Giles, Heather; Leff, Paul; Stepney, Raymond James; Singaram, Gonapushnie

PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK

SOURCE: Eur. Pat. Appl., 22 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 284202	A1	19880928	EP 1988-301474	19880222
EP 284202	B1	19930310		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 8812046	A	19880825	AU 1988-12046	19880222
JP 63253072	A	19881020	JP 1988-39324	19880222
ZA 8801224	A	19891025	ZA 1988-1224	19880222
AT 86615	T	19930315	AT 1988-301474	19880222
ES 2053721	T3	19940801	ES 1988-301474	19880222
PRIORITY APPLN. INFO.:			GB 1987-4158	A 19870223
			EP 1988-301474	A 19880222

OTHER SOURCE(S): MARPAT 110:75504


IT 118675-50-6P 118675-55-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as PGD2 antagonists)

RN 118675-50-6 CAPLUS

CN 4-Imidazolidineheptanoic acid, 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)- (CA INDEX NAME)







RN 118675-55-1 CAPLUS

CN 4-Imidazolidineheptanoic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



GI



AB The title compds. [I; R = C5-8 alkyl, C3-12 alkenyl, C4-8 cycloalkyl-C1-12 alkyl, (un)substituted C6 or C10 aryl, C6 or C10 aryl-C1-12 alkyl; R1 = CO2H, CONH2, C1-4 alkoxy carbonyl; R2 = R3CH2NH, R3CH:N; R3 = R4CO, R4R5CH; R4 = C3-8 alkyl, C3-8 alkenyl, C4-8 cycloalkyl, 5- or 6-membered heterocyclyl, (un)substituted Ph, phenyl-C1-4 alkyl; Z = CH2CH2, cis- or trans-CH:CH; Z1 = bond, C1-6 alkylene with 1 CH2 optionally replaced by O, S] and their salts and solvates were prepared as prophylactic or therapeutic agents which antagonize the physiol. effects of PGD2, useful against mast cell dysfunctions such as mastocytosis or allergic rhinitis. PhCH:NNHCONH2 and di-Et 2-bromononanedioate were refluxed in EtOH containing NaOEt to give I [R = H, R1 = CO2Et, R2 = PhCN:N, ZZ1 = (CH2)5] which was converted in 6 steps to title compound II. In washed human blood platelets II is a simple competitive antagonist of PGD2 with pKB of 9.26 (equilibrium dissociation constant at the PGD2 receptor).

=> FIL STNGUIDE  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
152.83	331.40

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-21.60	-21.60

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 01:25:05 ON 18 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Aug 8, 2008 (20080808/UP).

=>  
=>  
=> d his

(FILE 'HOME' ENTERED AT 01:21:58 ON 18 AUG 2008)

FILE 'REGISTRY' ENTERED AT 01:22:08 ON 18 AUG 2008

L1	STRUCTURE UPLOADED
L2	0 S L1 SSS SAM
L3	3 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 01:23:00 ON 18 AUG 2008

L4	27 S L3
L5	623299 S FOOD OR DIET
L6	0 S L5 AND L4

FILE 'STNGUIDE' ENTERED AT 01:25:05 ON 18 AUG 2008